Editas Medicine (EDIT) Stock
Biotech company developing gene editing therapies for diseases. Here's the price, business snapshot, and what's worth knowing about Editas Medicine in October 2026.
Editas Medicine (EDIT) is a clinical-stage biotechnology company focused on developing gene-editing therapies using CRISPR-based technologies. The firm aims to correct disease-causing genetic variants for rare and common disorders, with a pipeline that includes in‑vivo and ex‑vivo programmes. As of the given market data, Editas is a small-cap company (market cap ~ $349m), which often means higher share-price volatility and greater sensitivity to clinical and funding news. Key points for investors: clinical-trial results, regulatory decisions, partnership announcements and financing plans can materially affect the stock. There is the potential for significant upside if trials succeed, but also a meaningful risk of setbacks, delays and dilution. This summary is for educational purposes only and not personal investment advice; always consider your risk tolerance, time horizon and consult a qualified adviser before making decisions.
Editas Medicine (EDIT) Stock Forecast
Analyst price target, next 12 months
$7.29
+178.1% vs today's $2.62
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Editas Medicine have a consensus 12-month target of $7.29, above the current price of $2.62.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Editas Medicine’s stock with a target price of $7.29, indicating good growth potential.
Financial Health
EDITAS Medicine is generating modest revenue and cash flow, but its financial position shows room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage Pipeline
Several programmes are in or approaching clinical evaluation, so trial readouts can be major catalysts — though outcomes can also disappoint.
Catalysts and Risks
Near-term catalysts include study results and partnerships; balance this with regulatory uncertainty and potential dilution from fundraising.
Technology Potential
CRISPR-based approaches aim to address genetic disease at the source, offering transformative potential, but commercial and safety hurdles remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
